Online citations, reference lists, and bibliographies.

Drug-Eluting Stents For Treatment Of Peripheral Artery Disease

Kazeen Abdullah, Bassel Bou Dargham, Micah Steinbrecher, Bo Sun, Zhao Hui-qiang, Houman Khalili, Emmanouil S. Brilakis, Subhash Banerjee
Published 2018 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Endovascular intervention is a mainstay treatment of peripheral artery disease (PAD) in addition to aggressive risk factor modification and exercise programs in patients with favorable anatomy or in those who are considered too high risk for surgical intervention. Treatment with percutaneous transluminal angioplasty (PTA) and bare metal stents (BMS) has been limited by high rates of in-stent restenosis (ISR) requiring repeat revascularization. Drug-eluting stents (DES), developed and designed to reduce ISR, offer a promising solution to the current challenges in endovascular management of PAD. Several randomized clinical trials have shown improved short- and mid-term outcomes with DES as compared with both PTA and BMS. Herein we provide an up-to-date review of the current literature on DES use in PAD.
This paper references
10.1016/j.jacc.2012.04.035
Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial.
Aljoscha Rastan (2012)
10.1016/j.jacc.2017.10.010
3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial.
Dean J. Kereiakes (2017)
10.1016/j.jvs.2009.09.031
AMS INSIGHT—Absorbable Metal Stent Implantation for Treatment of Below-the-Knee Critical Limb Ischemia: 6-Month Analysis
Marc Bosiers (2009)
10.1016/j.jcin.2014.05.008
Drug delivering technology for endovascular management of infrainguinal peripheral artery disease.
Karan Sarode (2014)
10.1161/CIRCULATIONAHA.115.016900
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery
Michael D. Dake (2016)
10.1177/1358863X17701592
2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary
Marie D. Gerhard-Herman (2017)
10.1016/j.jcin.2015.09.035
Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 12-Month Results.
Hiroyoshi Yokoi (2016)
10.1007/s00270-018-2110-1
Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results
Kimihiko Kichikawa (2018)
10.1016/j.jcin.2014.04.015
Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial.
Dimitris Siablis (2014)
10.1016/j.jcin.2013.09.009
Evaluation of the biodegradable peripheral Igaki-Tamai stent in the treatment of de novo lesions in the superficial femoral artery: the GAIA study.
Martin Werner (2014)
10.1161/CIR.0000000000000657
Correction to: Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery 5-Year Results of the Zilver PTX Randomized Trial.
(2019)
10.1016/j.jacc.2009.11.072
Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents: the PaRADISE (PReventing Amputations using Drug eluting StEnts) trial.
Andrew J. Feiring (2010)
10.1161/CIRCULATIONAHA.114.011004
Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease
Gunnar Tepe (2015)
10.1583/05-1704.1
Drug-Eluting and Bare Nitinol Stents for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery: Long-Term Results from the SIROCCO Trial
Stephan H. Duda (2006)
10.1186/1745-6215-15-423
Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial
Yann Gouëffic (2014)
10.1016/j.jcin.2016.02.051
Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I): 2-Year Clinical and Imaging Results.
Johannes Lammer (2016)
10.1056/NEJMoa1406235
Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
Kenneth Rosenfield (2015)
10.1161/hc3601.093987
Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model.
Taizo Suzuki (2001)
The Eluvia drug-eluting vascular stent system
D. Athanasios (2016)
10.1016/j.jcin.2017.01.028
2-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
Antonio Micari (2017)
10.1016/j.amepre.2006.12.010
Ethnic-specific prevalence of peripheral arterial disease in the United States.
Matthew A. Allison (2007)
10.1161/CIRCINTERVENTIONS.111.962324
Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results.
Michael D. Dake (2011)
10.1016/s0098-1672(08)70418-1
Bypass Versus Angioplasty in Severe Ischaemia of the Leg (BASIL): Multicentre, Randomised Controlled Trial
Geoffrey A. Gardiner (2006)
Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model
鈴木 健 (2003)
10.1016/j.jvs.2011.07.099
Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease.
Marc Bosiers (2012)
10.1056/nejmc1711903
Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.
Gian Battista Danzi (2017)
10.1001/jama.2012.13415
Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men.
Michel M Joosten (2012)
10.1161/CIRCINTERVENTIONS.114.002376
Percutaneous Transluminal Angioplasty and Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia (PADI) Trial
Marlon I. Spreen (2016)
10.1016/j.jvs.2015.03.002
Drug-Coated Balloon versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and/or Popliteal Peripheral Artery Disease: 12-Month Results From the IN.PACT SFA Randomized Trial
Gunnar Tepe (2015)
10.1161/CIRCULATIONAHA.111.033886
Medical therapy in peripheral artery disease.
Jeffrey S Berger (2012)
10.1016/j.jacc.2013.03.034
Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies.
Michael D. Dake (2013)
10.1016/j.jcin.2016.06.005
Experience With the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Arteries Below the Knee: 12-Month Clinical and Imaging Outcomes.
Ramon L. Varcoe (2016)
10.1016/j.jvs.2011.01.047
First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease.
Johannes Lammer (2011)
10.2147/vhrm.1.1.73.58932
Restenosis After Percutaneous Angioplasty: The Role of Vascular Inflammation
Martin Schillinger (2005)
Drug-coated balloons: hope or hype
T. Zeller (2012)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar